Skip to main content
. Author manuscript; available in PMC: 2015 Jan 15.
Published in final edited form as: Biomacromolecules. 2013 Oct 28;14(11):4108–4115. doi: 10.1021/bm4012425

Figure 9.

Figure 9

Enhanced splice-switching in an engineered human cancer cell line (A375 pLuc) enhances SSO delivery. SSO in nanocomplexes with mPEG-PAMAM-G4 and lipofectamine (10:1/Lipo or 5:1/Lipo) provided more splicing correction and hence cell luminescence27, in comparison to Lipofectamine (Lipo) or mPEG-PAMAM-G4 controls at either 10:1 or 5:1 N/P ratios. RLU: Relative light units. P-value of <.0001***. P-value of <.005**, indicates significance of SSO delivery for 10:1/Lipo or 5:1/Lipo in comparison to Lipo only control.